Skip to main content

Advertisement

Table 1 Patient demographics at the time of bDMARD discontinuation

From: Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study

Type of biologic All TNFi(mAb) TNFi(R/P) CTLA4-Ig IL-6Ri p value
  (N = 181) (N = 95) (N = 32) (N = 17) (N = 37)
Age (years) 49.0 ± 16.7 50.8 ± 15.7 45.9 ± 17.5 49.4 ± 18.2 46.8 ± 18.3 0.42
Female sex, n (%) 144 (79.6) 77 (81.1) 27 (84.4) 12 (70.6) 28 (75.7) 0.62
Disease duration (years) 7.6 ± 9.2 5.3 ± 6.9 11.2 ± 11.5 8.0 ± 7.8 10.2 ± 11.3 < 0.01
Current smoking, n (%) 11 (11.1) 9 (17.3) 0 (0) 1 (9.1) 1 (4.2) 0.19
bDMARD-naïve, n (%) 118 (65.2) 76 (80.1) 18 (56.3) 11 (64.7) 18 (48.6) < 0.01
Discontinuation due to remission, n (%) 34 (18.8) 25 (26.3) 4 (12.5) 3 (17.6) 2 (5.4) 0.03
Remission maintenance period (days) 130.6 ± 185.0 162.0 ± 211.0 125.3 ± 155.8 98.3 ± 140.2 69.5 ± 135.7 0.06
DAS28-CRP 1.6 ± 0.4 1.5 ± 0.39 1.7 ± 0.4 1.7 ± 0.4 1.7 ± 0.4 < 0.01
Boolean remission achieved, n (%) 61 (33.7) 34 (35.8) 18 (56.3) 1 (5.9) 8 (21.6) < 0.01
MTX use, n (%) 142 (78.5) 70 (73.7) 29 (90.6) 10 (58.8) 33 (89.2) 0.01
MTX dose (mg/week) 7.1 ± 2.9 8.3 ± 3.0 7.5 ± 2.4 9.0 ± 3.6 7.5 ± 2.6 0.11
Glucocorticoid use, n (%) 77 (42.5) 40 (42.1) 8 (25.0) 12 (70.6) 17 (45.9) 0.02
Glucocorticoid dose (mg/day) 5.9 ± 9.5 7.4 ± 12.9 4.5 ± 3.6 4.9 ± 2.0 3.9 ± 2.2 0.44
ACPA positive, n (%) 125 (86.2) 68 (89.5) 26 (34.2) 8 (53.3) 26 (86.7) 0.54
RF positive, n (%) 114 (77.0) 57 (75.0) 15 (62.5) 13 (86.7) 29 (87.9) 0.04
  1. Demographic and clinical characteristics at the time of bDMARD discontinuation summarized as means ± standard deviations for continuous data and as numbers (percentages) for categorical data. Analysis of variance and the chi-squared test were used to compare the clinical characteristics among different groups for continuous variables and categorical variables, respectively
  2. bDMARD biological disease-modifying antirheumatic drug, TNFi(mAb) monoclonal antibodies against TNF (infliximab, adalimumab, and golimumab), TNFi(R/P) soluble TNF receptor or Fab fragments against TNF fused with polyethylene glycol (etanercept and certolizumab), CTLA4-Ig abatacept, IL-6Ri interleukin-6 receptor inhibitor (tocilizumab), DAS28-CRP Disease Activity Score 28—C-reactive protein, MTX methotrexate, ACPA anti-citrullinated protein antibodies, RF rheumatoid factor, TNF tumor necrosis factor